Risks may be opportunities
Pharmaceutical CEOs are more likely to see the spread of infectious diseases and demographic shifts as potential opportunities for growth. Both trends will stimulate demand for medicines, while the rising incidence of chronic diseases like obesity and diabetes will provide new ways of generating revenues by moving into health management.
In-depth CEO story
 Fred Hassan
Chairman and CEO, Schering-Plough Corporation, US
Regulatory evolution
Most pharmaceutical companies already collaborate with governmental and non-governmental organisations to a greater extent than companies in other sectors. Pharmaceutical CEOs report that such external stakeholders have a stronger influence than they did three years ago.
|
The long-term picture
Many pharmaceutical CEOs are cautiously optimistic about the long term. Eighty-one percent believe that the world's economic axis is shifting, and that a new set of countries will emerge to challenge the economic, political, and cultural power of the G8.
Recruiting and retaining skilled scientists is key
The pharmaceutical industry is heavily dependent on innovation, so recruiting and retaining skilled scientists will always be a key priority.
Rebuilding its reputation
Healthcare professionals and patients will not trust the pharmaceutical industry to provide services unless they are sure that it has their best interests at heart.
Related research from PricewaterhouseCoopers
|
